

## Enabling a world free from the burden of NTDs

The Global Public Health team at Johnson & Johnson is supporting global efforts to address the burden of NTDs by expanding treatment access and accelerating R&D.



### THE CHALLENGE

Neglected tropical diseases (NTDs) are a group of 20 communicable, often-debilitating conditions that affect more than 1.7 billion people in nearly 150 countries around the world. These diseases disproportionately impact women, children and other vulnerable communities in limited-resource countries, including populations living in poverty and in areas without adequate access to clean water and sanitation. With the emergence of climate change, NTDs could threaten even more people in more places as increasing global temperatures make it possible for certain NTDs, like dengue, to spread from their native regions to new regions. NTDs have a considerable impact on the lives of the people they affect, contributing to significant morbidity and long-term loss of economic productivity.

### OUR RESPONSE

Johnson & Johnson has been at the forefront of the fight against NTDs for more than 15 years. In 2006, we began donating our medicine for intestinal worms, or soil-transmitted helminths (STH) infections — the most widespread of all NTDs and which have a particularly damaging impact on the health and development of children.

In 2012, Johnson & Johnson signed the London Declaration on NTDs, a landmark, first-of-its-kind public-private partnership and committed to provide 200 million doses of our STH medicine annually through 2020 and have since extended this commitment through 2025. Despite the challenges imposed by the COVID-19 pandemic, we have continued meeting our commitments, and to date, Johnson & Johnson has donated more than 2 billion doses of our STH medicine to more than 60 countries across Africa, Asia, Latin America and the Middle East.

Johnson & Johnson is also continuing to advance innovative solutions for other NTDs. We are accelerating the development of new preventive and therapeutic options for dengue and are exploring simplified therapeutic options for leprosy.

Building on our longstanding legacy, in 2022, we joined with the global NTD community to sign the Kigali Declaration on NTDs, reaffirming our commitment to collaborate from the lab to the last mile of health delivery to drive progress toward addressing the burden of these diseases and help create a prosperous and safer future for communities across the globe.

### BY THE NUMBERS

Johnson & Johnson is tackling three WHO-identified NTDs impacting underserved people and communities around the globe.

**1.5B**  
people affected worldwide by STH, or intestinal worms, including approximately 835 million children

UP TO  
**400M**  
people infected annually by dengue fever, a mosquito-borne viral disease

**140,000**  
new cases of leprosy in 2021 alone, an under-addressed disease that results in skin lesions and significant disability

### OUR IMPACT AGAINST INTESTINAL WORMS

#### 2.2 BILLION DOSES

of our medicine for intestinal worms donated since 2006

#### 200 MILLION DOSES

of our medicine for intestinal worms donated each year

#### 60+ COUNTRIES

receiving our medicine through our donation program

## OUR ENDURING COMMITMENT

Johnson & Johnson joined with the public and private sectors in signing the 2022 Kigali Declaration, reaffirming our longstanding commitment in the global fight against NTDs. In signing the Declaration, Johnson & Johnson proudly pledged to:

- Donate up to 200 million doses annually of our Janssen Pharmaceutical Companies' medicine to treat intestinal worm infections, through 2025; and to
- Advance novel R&D programs to discover new medicines needed to beat dengue and leprosy.

### Spotlight on: Treatment Access



**Reaching children:** In 2006, Johnson & Johnson collaborated with the Task Force for Global Health to establish Children Without Worms, the first program focused exclusively on reducing intestinal worms in school-aged children, and began donating our medicine. In 2012, we increased our donation commitment to 200 million doses annually to children in need and have extended this commitment through 2025.



**Advancing pediatric formulations:** In 2019, we introduced an innovative pediatric-friendly formulation of our medicine that is both chewable and dispersible, allowing for ease of dosing for children as young as 1 year of age. Our donation program fully switched to the chewable formulation in 2021.



**Strengthening health systems:** We've worked with organizations like BRAC and the END Fund to support the training of community health workers in underserved communities, helping to build the capacity of local health systems to treat and diagnose intestinal worms.

### Spotlight on: Innovation



**Advancing dengue research:** Since 2007, we've been working to advance research to address the unmet need for prevention and treatment options for dengue. Our early-stage clinical candidate (JNJ-1802) has progressed to Phase 2 clinical studies, with data showing the compound to provide strong protection against dengue in non-human primates and mice and to be safe and well-tolerated in humans.



**Investing in local scientific capacity:** In June 2022, Johnson & Johnson launched the first Satellite Center for Global Health Discovery in Asia at Duke-NUS Medical School in Singapore, which aims to stimulate the early-stage science, innovation and talent development needed to tackle flaviviruses, including dengue, yellow fever, Zika and other pandemic threats.



**Exploring improved leprosy treatment:** We are supporting a proof-of-concept Phase 2 study called WAVE that is assessing the safety, pharmacokinetics and efficacy of eight weeks of bedaquiline monotherapy, followed by 12 months of a WHO recommended regimen for the treatment of leprosy. Preliminary data found the compound to be well-tolerated and safe. The trial is fully enrolled with a primary completion date in 2023.

## ABOUT J&J GLOBAL PUBLIC HEALTH

Through a dedicated global public health (GPH) organization that combines R&D, global access strategies and programs, and local operations, Johnson & Johnson is putting the world's most vulnerable and underserved at the heart of everything we do—measuring our success in lives improved. As a team of innovators, we are committed to pioneering and sustainably delivering meaningful and transformational products.

Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges, and, ultimately, we hope to do our part to close the gap of inequity and pave the way to a healthier, more equitable future.

